Considering the wide spread of known and new pathogens of acute respiratory viral infections (ARVI), it is important to search for drugs that have a wide spectrum of antiviral activity and additionally the ability to act pathogenetically. Equally important is the confirmation of therapeutic activity in drugs known for their effectiveness and safety. In order to monitor the susceptibility of ARVI pathogens to the antiviral drug Influcid, a series of in vitro studies was performed. Materials and methods: classical virological controlled studies were performed using current strains of human influenza virus (A/Moscow/225/2019 (H1N1)pdm09 and B/Moscow/17/2019) and MDCK cell culture. Antiviral, cytoprotective (against viruses, antiviral and antipyretic drugs) properties of the Inflicid were evaluated by changing the logarithm of the tissue cytopathic infecting dose, which causes 50% of cells to be damaged (lgTCID50), as well as by changing the optical density when using tetrazolium dyes. Results and discussion: Influcid dose-dependently suppressed the reproduction of epidemic strains A/Moscow/225/2019(H1N1)pdm09 and B/Moscow/17/2019 by 50% at concentrations of 0, 34 and 0, 69-0, 86% vol., respectively. Also, the Influcid reduced the reproduction of human influenza virus strains: A/New Caledonia/20/99(H1N1), A/Victoria/35/72, Wisconsin/67/05(H3N2) and B/Malaysia/2506/04, reducing the titers by 0, 5-2, 5 lgTCID50 and Dengue virus DENV-2/RUS/TH-Novosibirsk02/2012. Influcid exerted a cytoprotective effect on cells infected with A/IIV-Moscow/01/2009 (H1N1)pdm09, increasing the proportion of surviving cells by 4-52, 0%. For cells infected with the pandemic strain A/California/07/09(H1N1)pdm09, there was a significant decrease in the cytopathic effect of the virus up to full protection with the «preventive» scheme of the drug application. In addition, the Influcid protected cells from the action of herpes viruses types I and II, type III adenovirus, parainfluenza virus, seasonal coronavirus and respiratory syncytial virus, toxic doses of umifenovir and rimantadine, and did not increase the cytotoxicity of acetaminophen and ibuprofen. Conclusion: having a combination of confirmed antiviral activity against current epidemic virus strains, cytoprotective action, the ability to exert a pathogenetic (immunomodulatory and anti-inflammatory) effect, as well as a favorable safety profile, Influcid may be a relevant and promising drug in the arsenal of medical practitioners.